May is Skin Cancer Awareness Month. And this year, we want to tell you about Ceejay. A mole on her thigh. A tanning bed habit, she thought, was harmless. A diagnosis that changed everything.   Christine, known as Ceejay, is a Stage IIIb melanoma survivor. Her cancer came back, spreading

Day 3 of ISPOR 2026 is live in Philadelphia — and today’s sessions are the ones rare disease evidence teams have been waiting for all week. The pipeline is growing. The evidence bar is rising. And the frameworks the industry relies on still weren’t built for populations this small. The

May is Cystic Fibrosis Awareness Month. Behind every CF diagnosis is a person who wakes up every day, does hours of treatments, takes handfuls of medications, and still shows up. Nearly 105,000 people worldwide live with this relentless genetic disease. They are supported by caregivers, providers, and fearless advocacy organizations

Asembia26 wraps today — and the conversations this week confirmed what the most prepared teams already know. Specialty pharma, market access, and rare disease strategy converged in Las Vegas. The signal was clear: the industry’s next chapter belongs to teams who stopped waiting on incomplete data. What this week made

🩸 1 in 10,000 males is born with hemophilia. Most still face fragmented data, delayed diagnoses, and invisible patient journeys. Today — World Hemophilia Day — we commit to changing that. This year, World Hemophilia Day falls in the middle of the Hemophilia Federation of America (HFA) Symposium 2026 in

Inder Jaggi, CEO of Clinakos Inc., spent an evening at Stanford’s Hoover Institution listening to Jensen Huang (NVIDIA), Congressman Ro Khanna, and General McMaster debate the future of AI in America. Here are 5 things that will reshape how Inder leads Clinakos: AI won’t kill jobs — the wrong narrative

Bots can fake survey answers. They can’t fake Integrated Patient Data™. Meet Confirmis — the next evolution in diagnosis verification powered by Clinakos’ Integrated Patient Data™ and Medically Smart AI™. We connect longitudinal, near-real-time records across EHRs, pharmacies, labs, payers, and more to create Patient360 profiles built on real clinical

The Rare Disease Data Crisis: 80–90% Invisible. 100% Impactful. Above the Waterline (What You See): Claims & EMR data covering only 10–20% of ultra-rare patients. Average 5–7 years from symptom to diagnosis. Small populations: fewer than 20K subpopulations per rare oncology disease.   Below the Surface (The Hidden Crisis): 18–24

Colorectal cancer is now the leading cause of cancer death in U.S. adults under 50 — at a time when overall cancer mortality in this age group is actually going down. ⚠️ This Colorectal Cancer Awareness Month, findings from the JAMA research letter “Leading Cancer Deaths in People Younger Than

  It’s a wrap on the 2026 Intellus Worldwide Summit. ✅ Three days. Dozens of sessions. One signal that kept repeating: Pharma insights teams continue to make critical decisions on incomplete patient data. Further, they are actively increasing their use of AI every day.  Here are the 5 moments that